𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Growth factors modify the epidermal growth factor receptor through multiple pathways

✍ Scribed by BethAann Friedman; Marsha Rich Rosner


Publisher
John Wiley and Sons
Year
1987
Tongue
English
Weight
618 KB
Volume
34
Category
Article
ISSN
0730-2312

No coin nor oath required. For personal study only.

✦ Synopsis


Previous results have shown that tumor promoters modify the properties of the epidermal growth factor (EGF) receptor through the activation of protein kinase C . Diacylglycerol-generating factors such as platelet-derived growth factor (PDGF) and p28"' should activate protein kinase C and alter EGF receptor properties in a similar manner. To test directly the involvement of protein kinase C in the action of media from v-sis-transformed cells on the EGF receptor, Swiss 3T3 cells were first extensively treated with various concentrations of the tumor-promoter phorbol dibutyrate (PDBu) This treatement reduced levels of active protein kinase C in the cells, making them less responsive to subsequent rechallenge with the tumor promoter. The results demonstrate that there are at least two components to the action of media from v-sis transformed cells on EGF binding: a labile factor that confers protein kinase C independence and a stable factor that appears to be dependent on protein kinase C. The action of the first factor cannot be mimicked by transforming growth factor-p or EGF in either the presence or absence of PDGF. The action of the second factor is similar to that of PDGF. These findings indicate that heterologous regulation of the EGF receptor can occur through both protein kinase C-dependent and -independent pathways.


πŸ“œ SIMILAR VOLUMES


Epidermal growth factor receptors
✍ A. P. Savage; T. Cooke; R. Sainsbury; J. Farndon; A. Harris πŸ“‚ Article πŸ“… 1985 πŸ› John Wiley and Sons 🌐 English βš– 138 KB πŸ‘ 1 views
The epidermal growth factor receptor con
✍ Jason A. Wilken; Andre T. Baron; Nita J. Maihle πŸ“‚ Article πŸ“… 2010 πŸ› John Wiley and Sons 🌐 English βš– 86 KB πŸ‘ 1 views
Modulation of the epidermal growth facto
✍ Pamela A. Maher πŸ“‚ Article πŸ“… 1993 πŸ› John Wiley and Sons 🌐 English βš– 883 KB

Institute for Diabetes and Endocrinology, La lolla, California 92(1.?7 Treatment of Swiss 3T3 fibroblasts with basic fibroblast growth factor (bFGF) lead to a rapid reduction in epidermal growth factor (EGF) binding and a slower inhibition of EGF receptor autophosphorylation. The reduction in bindi

Transforming growth factor-alpha short-c
✍ Xiaomei Ouyang; Timothy Gulliford; Guocai Huang; Richard J. Epstein πŸ“‚ Article πŸ“… 1999 πŸ› John Wiley and Sons 🌐 English βš– 153 KB πŸ‘ 2 views

Transforming growth factor-alpha (TGF␣) is an epidermal growth factor receptor (EGFR) ligand which is distinguished from EGF by its acid-labile structure and potent transforming function. We recently reported that TGF␣ induces less efficient EGFR heterodimerization and downregulation than does EGF (

Tenascin cytotactin epidermal growth fac
✍ Anand Krishnan V. Iyer; Kien T. Tran; Christopher W. Borysenko; Michael Cascio; πŸ“‚ Article πŸ“… 2007 πŸ› John Wiley and Sons 🌐 English βš– 563 KB

## Abstract Select epidermal growth factor (EGF)‐like (EGFL) repeats of human tenascin cytotactin (tenascin C) can stimulate EGF receptor (EGFR) signaling, but activation requires micromolar concentrations of soluble EGFL repeats in contrast to subnanomolar concentrations of classical growth factor